Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing innovative, non-addictive pain management solutions and treatments for central nervous system disorders. The company leverages proprietary drug delivery technologies to optimize patient care and address unmet medical needs in various therapeutic areas, including postoperative pain, severe pain, and rare pediatric epilepsy. As a preclinical-stage pharmaceutical company, Virpax is dedicated to enhancing compliance and optimizing its product candidates through novel drug delivery systems.
Industries
Nr. of Employees
small (1-50)
Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300, Berwyn, PA 19312
Products
Probudur
Injectable long‑acting liposomal formulation of a local anesthetic developed for wound‑site administration to provide extended postoperative analgesia in preclinical studies.
Envelta (NES100)
Intranasal peptide formulation using nanoparticle molecular envelope technology to deliver enkephalin‑based peptides to the brain for management of acute and chronic pain.
NobrXiol
Intranasal pharmaceutical‑grade cannabidiol formulation using nanoparticle delivery intended for management of rare pediatric epilepsy indications.
AnQlar (consumer OTC candidate)
High‑density intranasal spray developed as a mucoadhesive, positively charged nanoparticle dispersion intended to act as a barrier and inhibit replication of negatively charged respiratory viruses.
Epoladerm
Topical diclofenac spray film formulation developed as a consumer/OTC product candidate for localized treatment of osteoarthritis pain.
Probudur
Injectable long‑acting liposomal formulation of a local anesthetic developed for wound‑site administration to provide extended postoperative analgesia in preclinical studies.
Envelta (NES100)
Intranasal peptide formulation using nanoparticle molecular envelope technology to deliver enkephalin‑based peptides to the brain for management of acute and chronic pain.
NobrXiol
Intranasal pharmaceutical‑grade cannabidiol formulation using nanoparticle delivery intended for management of rare pediatric epilepsy indications.
AnQlar (consumer OTC candidate)
High‑density intranasal spray developed as a mucoadhesive, positively charged nanoparticle dispersion intended to act as a barrier and inhibit replication of negatively charged respiratory viruses.
Epoladerm
Topical diclofenac spray film formulation developed as a consumer/OTC product candidate for localized treatment of osteoarthritis pain.
Services
Collaborative research and development agreements with government research organizations to support preclinical development, manufacturing and testing of product candidates.
Engagement of external advisors to identify global sublicense partners for OTC and consumer health product candidates and to pursue strategic partnerships for Rx products.
Collaborative research and development agreements with government research organizations to support preclinical development, manufacturing and testing of product candidates.
Engagement of external advisors to identify global sublicense partners for OTC and consumer health product candidates and to pursue strategic partnerships for Rx products.
Expertise Areas
- Targeted drug‑delivery platforms
- Liposomal formulation development
- Nose‑to‑brain intranasal delivery
- Preclinical efficacy and safety studies
Key Technologies
- Liposomal encapsulation
- Polymeric nanoparticle (molecular envelope) technology
- Intranasal spray and dry‑powder delivery
- Topical spray‑film formulation
News & Updates
Virpax announced results from a minipig Dose Range Finding study for Probudur, demonstrating positive tolerance and no adverse effects.
Virpax has been granted an extension of its cooperative research and development agreement with NCATS for the continued development of NES100.
Virpax announced results from a minipig Dose Range Finding study for Probudur, demonstrating positive tolerance and no adverse effects.
Virpax has been granted an extension of its cooperative research and development agreement with NCATS for the continued development of NES100.